GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Glucagon-like peptide-1 receptor agonist-associated HF risk reduction is primarily mediated by BMI reduction rather than glucose control, but not fully explained by either. Residual effects after BMI and T2D adjustment suggest direct cardioprotective actions, supporting trials in non-obese, non-diabetic HF patients.
Authors
- Chang Li (ORCID: https://orcid.org/0000-0002-3267-1859)
- Neng Li Dai
- Wufeng Cai
- Xin Deng (ORCID: https://orcid.org/0000-0001-7846-7389)
- Z. Li (ORCID: https://orcid.org/0000-0002-3744-7602)
- Yunqian Yao (ORCID: https://orcid.org/0000-0003-4353-4398)
- Xinyu Zhao (ORCID: https://orcid.org/0000-0002-5128-4424)
- Junbo Ge (ORCID: https://orcid.org/0000-0002-8318-4882)
- Weidong Xiong (ORCID: https://orcid.org/0009-0000-4244-3713)
- Yongchao Zhao
- Shuai Song
- Hao Lu
- Yiqing Hu
- You Zhou
- Xinyu Weng
- Aijun Sun
Institutions
- Shanghai Medical College of Fudan University (CN)
- Zunyi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Exeter (GB)
- Sichuan University (CN)
- Fudan University (CN)
- Wuhan University (CN)
- West China Hospital of Sichuan University (CN)
- Shanghai Medical Information Center (CN)
- Eye & ENT Hospital of Fudan University (CN)
- Shanghai Xuhui Central Hospital (CN)
- Institute of Genetics and Developmental Biology (CN)
- Zhongshan Hospital (CN)
- Renmin Hospital of Wuhan University (CN)
- Fu Wai Hospital (CN)
- The Orthopaedic Institute (US)
- Affiliated Hospital of Zunyi Medical College (CN)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-12-13
- DOI
- https://doi.org/10.1093/eurheartj/ehaf1066
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29